Apolipoprotein A-1 in the treatment of acute myocardial infarction

With the gradual rejuvenation and rising popularity of acute myocardial infarction, more and more researchers have begun to investigate novel treatments for this disease. The treatment plan for continuing to increase high-density cholesterol based on apolipoprotein A-1 is gradually recognized by more and more people because of its theoretical and clinical practicability. However, there are relatively fewer experiments demonstrating the viability of apolipoprotein A-1 in clinical treatment compared to aspirin, ticlopidine, clopidogrel, and PTCA (percutaneous transluminal coronary angioplasty), which are mature technologies, and the summary of various clinical data is also far from sufficient. Therefore, apolipoprotein A-1 therapy is not widely used in the treatment of acute myocardial infarction yet. To fill this gap, this review will state the important clinical trials of apolipoprotein A-1 in treating acute myocardial infarction. in recent decades, summarize its clinical information, and analyze its proof of the feasibility for apolipoprotein therapy. Additionally, this review will assess the benefits and drawbacks of apolipoprotein A-1 therapy and currently available mature therapies (such as aspirin, ticlopidine and clopidogrel, PTCA). Therefore, it highlights the positive direction of apolipoprotein A-1 treatment and approaches in upcoming clinical experiments, assisting in apolipoprotein A-1 treatment's future rise to popularity.